CA
NZ
UK
AU
IND
US
…
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Compass Therapeutics is a clinical-stage biotechnology company developing antibody therapies for oncology and immune-mediated diseases with programs in clinical and preclinical development. Long-term growth drivers include successful advancement of trials, regulatory approvals, and strategic partnerships that could support commercialization. Investors may find exposure to novel biologics and pipeline upside appealing.
The company faces material risks from clinical trial failures, regulatory and commercialization uncertainty, high cash burn and likely need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
| Net income | -66.49M | -49.38M | -42.49M | -36.80M | -82.55M |
| Selling general administrative | 16.87M | 15.13M | 12.24M | 11.66M | 10.93M |
| Selling and marketing expenses | - | - | 11.04M | - | - |
| Gross profit | - | 0.85M | -1.89M | - | - |
| Reconciled depreciation | 1.47M | 1.75M | 1.89M | 1.90M | 1.62M |
| Ebit | - | -56.62M | -50.36M | -41.66M | -81.88M |
| Ebitda | -72.84M | -54.87M | -48.47M | -37.39M | -29.61M |
| Depreciation and amortization | - | 1.75M | 1.89M | 4.26M | 52.27M |
| Non operating income net other | - | - | - | 2.43M | -0.30M |
| Operating income | -72.84M | -56.62M | -50.36M | -41.66M | -81.88M |
| Other operating expenses | - | 57.48M | 50.36M | 41.66M | 31.26M |
| Interest expense | - | - | - | 2.36M | 0.37M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 6.40M | 7.30M | 7.87M | 2.36M | 0.03M |
| Net interest income | 6.40M | 7.30M | 7.87M | 2.36M | -0.34M |
| Non recurring | - | - | - | - | -50.62M |
| Income tax expense | - | - | - | -2.43M | 0.37M |
| Total revenue | 0.00M | 0.85M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 72.84M | 57.48M | 50.36M | 41.66M | 31.26M |
| Cost of revenue | - | - | 1.89M | - | - |
| Total other income expense net | 6.35M | 7.25M | 7.87M | 2.43M | -0.30M |
| Net income from continuing ops | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
| Net income applicable to common shares | - | - | - | -39.23M | -82.18M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M |
| Other current assets | 0.91M | 6.03M | 1.42M | 8.18M | 2.59M |
| Total liab | 22.80M | 15.17M | 8.34M | 18.01M | 13.68M |
| Total stockholder equity | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M |
| Other current liab | 11.38M | 6.29M | 2.51M | 11.69M | 8.78M |
| Common stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -431.17M | -364.68M | -315.31M | -272.81M | -233.59M |
| Other assets | - | - | - | 0.32M | 0.32M |
| Cash | 30.64M | 43.48M | 24.23M | 34.95M | 144.51M |
| Total current liabilities | 13.97M | 8.87M | 7.80M | 16.17M | 10.63M |
| Net debt | -20.81M | -36.85M | -22.50M | -32.01M | -140.48M |
| Short term debt | 1.00M | 0.34M | 1.20M | 1.10M | 0.99M |
| Short long term debt total | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M |
| Other stockholder equity | 627.66M | 489.69M | 463.80M | 454.74M | 373.66M |
| Property plant equipment | - | - | - | 1.57M | 6.33M |
| Total current assets | 209.82M | 132.75M | 153.88M | 194.79M | 147.10M |
| Net tangible assets | - | - | - | 181.64M | 140.08M |
| Short term investments | 178.26M | 83.24M | 128.23M | 151.66M | - |
| Net receivables | - | - | - | 0.32M | - |
| Accounts payable | 1.58M | 2.25M | 4.09M | 3.38M | 0.87M |
| Accumulated other comprehensive income | 0.28M | 0.21M | 0.04M | -0.30M | - |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -272.81M | -233.59M |
| Non currrent assets other | 0.57M | 0.57M | 0.32M | 0.32M | 0.32M |
| Non current assets total | 9.77M | 7.65M | 2.99M | 4.85M | 6.65M |
| Capital lease obligations | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -93.28M | 46.77M | 26.96M | -151.16M | -1.77M |
| Change to liabilities | - | - | - | 5.43M | -0.19M |
| Total cashflows from investing activities | -93.31M | 46.77M | 26.96M | -151.20M | -1.77M |
| Net borrowings | - | - | - | - | -9.38M |
| Total cash from financing activities | 129.61M | 17.34M | 2.94M | 75.76M | 118.61M |
| Change to operating activities | - | - | - | -3.78M | 6.44M |
| Net income | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
| Change in cash | -12.84M | 19.25M | -10.72M | -109.57M | 97.17M |
| Begin period cash flow | 44.05M | 24.23M | 34.95M | 144.51M | 47.34M |
| End period cash flow | 31.21M | 43.48M | 24.23M | 34.95M | 144.51M |
| Total cash from operating activities | -49.14M | -44.85M | -40.62M | -34.12M | -19.67M |
| Issuance of capital stock | 138.00M | 18.11M | 3.13M | 76.24M | 128.27M |
| Depreciation | -1.40M | 1.75M | 1.89M | 1.90M | 1.62M |
| Other cashflows from investing activities | - | - | 0.03M | 0.18M | -0.20M |
| Sale purchase of stock | - | - | -0.00M | 75.76M | 127.99M |
| Other cashflows from financing activities | 129.61M | -0.78M | -0.16M | -0.48M | -0.28M |
| Change to netincome | - | - | - | 5.26M | 54.65M |
| Capital expenditures | 0.03M | 0.04M | 0.03M | 0.21M | 1.57M |
| Cash flows other operating | - | - | - | -6.37M | 51.10M |
| Cash and cash equivalents changes | - | - | - | -109.57M | 97.17M |
| Change in working capital | 9.18M | -4.14M | -2.91M | -1.26M | 6.25M |
| Stock based compensation | 8.37M | 8.56M | 6.12M | 5.33M | 4.03M |
| Other non cash items | 10.38M | -1.65M | 5.97M | -0.87M | 0.04M |
| Free cash flow | -49.17M | -44.90M | -40.65M | -34.34M | -21.23M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics Inc. |
0.03 4.01% |
0.79 | - | - | 269.28 | 4.79 | 109.28 | -8.92 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
80 Guest Street, Boston, MA, United States, 02135
617 500 8099
39
| Name | Title | Year Born |
|---|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, CEO & Director | 1961 |
| Dr. Vered Bisker-Leib MBA, Ph.D. | Pres & COO | 1971 |
| Mr. Neil L. Lerner CPA | VP of Fin. | 1967 |
| Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corp. Sec. | NA |
| Anna Gifford | Communications Mang. | NA |
| Dr. Peter F. Moesta Ph.D. | Interim Head of CMC | NA |
| Dr. Vered Bisker-Leib M.D., MBA, Ph.D. | Chief Executive Officer | 1972 |
| Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, President of Research & Development and Vice Chair | 1961 |
| Mr. Neil L. Lerner CPA | Vice President of Finance | 1967 |
| Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corporate Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...